COMMUNIQUÉS West-GlobeNewswire

Curetis: Study Data Presented at ECCMID 2019 Confirm Clinical Benefits of Unyvero Platform
04/04/2019
Growing body of evidence shows benefits of Unyvero for antibiotic stewardship 8 new reports on European studies presented by clinical researchers using Unyvero HPN, ITI, BCU and IAI Amsterdam, the Netherlands; San Diego [...]
Grant of Options and RSUs and PDMR Dealings
04/04/2019
LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Motif Bio to Present Iclaprim Data at ECCMID 2019
04/04/2019
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four iclaprim abstracts have [...]
DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
04/04/2019
Montrouge, France, April 4, 2019 DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company [...]
DBV Technologies annonce le prix de son offre globale d’actions ordinaires, pouvant prendre la forme d’American Depositary Shares, pour un montant total de 70,4 millions de dollars américains (soit 62,7 millions d’euros)
04/04/2019
Montrouge, France, le 4 avril (08h00 CEST), 2019 DBV Technologies annonce le prix de son offre globale d’actions ordinaires, pouvant prendre la forme d’American Depositary Shares, pour un montant total de 70,4 millions [...]
NGM Bio Announces Pricing of Initial Public Offering
04/04/2019
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the [...]
Silk Road Medical Announces Pricing of Initial Public Offering
04/04/2019
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China
04/04/2019
LA JOLLA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
ReWalk Robotics Announces Pricing of Registered Direct Offering for $4,250,000
04/04/2019
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with [...]
Emerald Health Therapeutics signe une lettre d'intention pour la fourniture de cannabis au marché québecois
04/04/2019
VANCOUVER, Colombie-Britannique, 03 avr. 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH; OTCQX: EMHTF) a signé une lettre d'intention pour la fourniture de cannabis à la Société [...]
Harvard Bioscience Subsidiary Data Sciences International Wins Award for Best Achievement of Operational Excellence in Pharmaceuticals & Life Sciences
03/04/2019
Company Receives Honor at Business Transformation & Operational Excellence Industry Awards 2019 in Orlando, Florida HOLLISTON, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a division [...]
Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
03/04/2019
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, [...]
Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting
03/04/2019
Results from Phase 2/3 OSPREY Trial of PyL in Prostate Cancer Selected for an Oral Presentation NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing [...]
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
03/04/2019
HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy [...]
Allogene Therapeutics Announces April 2019 Investor Conference Schedule
03/04/2019
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies [...]
MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
03/04/2019
ROCKVILLE, MD, April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference
03/04/2019
BURLINGTON, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led [...]
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
03/04/2019
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, [...]
Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit
03/04/2019
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new [...]

Pages